Cargando…

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

BACKGROUND: Egypt has the highest prevalence of a difficult to treat chronic hepatitis C virus (HCV), genotype 4. Pretreatment factors could guide individualization of therapy which aids in treatment optimization and interleukin IL28B gene polymorphism has been shown to closely relate to HCV treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizk, Hanan H., Hamdy, Nadia M., Al-Ansari, Nadia L., El-Mesallamy, Hala O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839712/ https://www.ncbi.nlm.nih.gov/pubmed/27100663 http://dx.doi.org/10.1371/journal.pone.0153895

Ejemplares similares

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV
por: Lin, Chia-Chen, et al.
Publicado: (2017)

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
por: Menard, Amélie, et al.
Publicado: (2012)

Apelin Serum Level in Egyptian Patients with Chronic Hepatitis C
por: El-Mesallamy, Hala O., et al.
Publicado: (2011)

Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
por: Jia, Zhifang, et al.
Publicado: (2012)

Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2015)

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients
por: Rivero-Juarez, Antonio, et al.
Publicado: (2014)

Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2014)

Changes in miR-122 and Cholesterol Expression in Chronic Hepatitis C Patients after PegIFN-Alpha/Ribavirin Treatment
por: Sidorkiewicz, Malgorzata, et al.
Publicado: (2020)

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
por: Izumi, Namiki, et al.
Publicado: (2012)

The (FTO) gene polymorphism is associated with metabolic syndrome risk in Egyptian females: a case- control study
por: Khella, Mina S., et al.
Publicado: (2017)

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
por: Huang, Jing, et al.
Publicado: (2017)

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
por: Laouénan, C, et al.
Publicado: (2015)

Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4
por: Zekri, Abdel Rahman N, et al.
Publicado: (2007)

Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study
por: Lin, Chih Ying, et al.
Publicado: (2020)

Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial
por: Woo, Hyun Young, et al.
Publicado: (2022)

SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment
por: Aslam, Rabia, et al.
Publicado: (2016)

Evaluation of C-Reactive Protein, Endothelin-1, Adhesion Molecule(s), and Lipids as Inflammatory Markers in Type 2 Diabetes Mellitus Patients
por: El-Mesallamy, Hala, et al.
Publicado: (2007)

European vs. Egyptian HCV-4 Patients with Elevated Baseline HCV RNA, Treated with PEG-IFN-α2a and Ribavirin: The Role of Rapid and Early Virologic Response
por: Dimitroulopoulos, Dimitrios, et al.
Publicado: (2010)

1(OH) Vitamin D3 Supplementation Improves the Sensitivity of the Immune-Response during Peg-IFN/RBV Therapy in Chronic Hepatitis C Patients-Case Controlled Trial
por: Kondo, Yasuteru, et al.
Publicado: (2013)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients
por: Bokharaei-Salim, Farah, et al.
Publicado: (2016)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
por: Baumgarten, A, et al.
Publicado: (2010)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Cell-Based Regenerative Strategies for Treatment of Diabetic Skin Wounds, a Comparative Study between Human Umbilical Cord Blood-Mononuclear Cells and Calves' Blood Haemodialysate
por: El-Mesallamy, Hala O., et al.
Publicado: (2014)

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017)

Plasma Granzyme B in ST Elevation Myocardial Infarction versus Non-ST Elevation Acute Coronary Syndrome: Comparisons with IL-18 and Fractalkine
por: El-Mesallamy, Hala O., et al.
Publicado: (2013)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients
por: AbdelHamid, Sherihan, et al.
Publicado: (2021)

HTR1A, TPH2, and 5-HTTLPR Polymorphisms and Their Impact on the Severity of Depressive Symptoms and on the Concentration of Tryptophan Catabolites during Hepatitis C Treatment with Pegylated Interferon-α2a and Oral Ribavirin (PEG-IFN-α2a/RBV)
por: Pawlowski, Tomasz, et al.
Publicado: (2023)

Factors Associated with Hepatitis C Infection among Chronic HCV Egyptian Patients
por: W. ABD EL-WAHAB, Ekram, et al.
Publicado: (2014)

Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population
por: Khalil, BM, et al.
Publicado: (2016)

MicroRNAs as Predictor Markers for Response to Interferon Treatment of Chronic Hepatitis C Genotype-4 in Egyptian Patients
por: Motawi, Tarek M. K., et al.
Publicado: (2015)

Prevalence of HCV genotypes in district Mardan
por: Afridi, Suliman Qadir, et al.
Publicado: (2013)

Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis
por: Abdel-Hafiz, Samah Mamdouh, et al.
Publicado: (2018)

IFN-Alpha Receptor-1 Upregulation in PBMC from HCV Naïve Patients Carrying CC Genotype. Possible Role of IFN-Lambda
por: Lalle, Eleonora, et al.
Publicado: (2014)

RBV: Read balance validator, a tool for prioritising copy number variations in germline conditions
por: Whitford, Whitney, et al.
Publicado: (2019)

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population
por: Jin, Young-Joo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hhlkmo41k083elf40ljhsc4edi